| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07221474 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in… |
Trial sites expanded: 47 -> 51 locations |
| 2026-05-27 | NCT07221474 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in… |
Trial sites expanded: 43 -> 46 locations |
| 2026-05-14 | NCT07513376 A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated… |
Recruitment opened |
| 2026-05-14 | NCT07513376 A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated… |
Trial sites expanded: 0 -> 3 locations |
| 2026-05-14 | NCT07221474 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in… |
Trial sites expanded: 32 -> 43 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in… | Carcinoma, Non-Small-Cell Lung | Recruiting |
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus… | Non-small Cell Lung Cancer | Recruiting |
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated… | Non-small Cell Lung Cancer | Recruiting |
| Phase 2 | |||
| NCT06961006 | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With… | Malignant Melanoma | Recruiting |
| NCT06833073 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer… | Urinary Bladder Neoplasms | Recruiting |
| NCT07221474 | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in… | Squamous Non-small Cell Lung Cancer | Recruiting |
| Phase 1/2 | |||
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With… | Bladder Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT03313778 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in… | Solid Tumors | Active, Not Recruiting |